By: Staff Reporter From: precisiononcologynews.com Tyme Technologies said on Monday it has dosed the first patient in its Phase II OASIS trial of SM-88 in previously treated metastatic hormone receptor (HR)-positive HER2-negative breast cancer patients. The investigator-initiated study at Georgetown University will initially enroll 30 patients with metastatic HR-positive HER2-negative breast cancer who have previously received at least two lines …
-
-
The Effects of Abuse in Shaping Cancer in the Future
-
Breast Cancer and the Children in Our Lives
-
Sharing Your Medical History Within Your Family
-
The Passage of Time in Our Lives
-
Do Some Celebrate the 4th of July as “Dependence” Day?
